Anthony Sedgwick France

Pierre Fabre Fund for Innovation is a new Open Innovation initiative targeting biotech companies, startups and research laboratories (public or private) specialized in oncology or dermatology, two of the core therapeutic activities of Pierre Fabre R&D group.

Pierre Fabre Fund for Innovation supports R&D projects either within 24 months from reaching clinical development or at early stage of clinical development. The support consists of diverse forms of collaboration: sharing Pierre Fabre’s expertise over the full pharmaceutical value chain, co-financing of the research program, taking minority equity participation or negotiating license agreements.

Company Type
Year Founded
2016
Management Team

Laurent Audoly, Managment partner

Vincent Serrra, Executive Partner

Tony Sedwick, Advisor

Pierre Fabre Fund for Innovation
Partner 

Dr Vincent Serra France

Pierre Fabre Fund for Innovation is a new Open Innovation initiative targeting biotech companies, startups and research laboratories (public or private) specialized in oncology or dermatology, two of the core therapeutic activities of Pierre Fabre R&D group.

Pierre Fabre Fund for Innovation supports R&D projects either within 24 months from reaching clinical development or at early stage of clinical development. The support consists of diverse forms of collaboration: sharing Pierre Fabre’s expertise over the full pharmaceutical value chain, co-financing of the research program, taking minority equity participation or negotiating license agreements.

Company Type
Year Founded
2016
Management Team

Laurent Audoly, Managment partner

Vincent Serrra, Executive Partner

Tony Sedwick, Advisor

Dr Vincent Serra
Pierre Fabre Fund for Innovation
LinkedIn logo Executive Partner 
Biography

A CEO of major international biotech companies, as well as co-founder and shareholder of ABIVAX. An optimization expert in innovation cycle, from the early identification of molecules with a high potential for value creation who could benefit patients and shareholders in the long term, to their final release on the international market. A business valuation specialist of companies who hold a portfolio of innovative products, through their listing on a stock market or following their potential takeover. Executive partner of the Pierre Fabre Fund for Innovations.